51
|
Lee HS, Choi GH, Joo DJ, Kim MS, Kim SI, Han KH, Ahn SH, Kim DY, Park JY, Choi JS. Prognostic value of model for end-stage liver disease scores in patients with fulminant hepatic failure. Transplant Proc 2014; 45:2992-4. [PMID: 24157020 DOI: 10.1016/j.transproceed.2013.08.036] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BACKGROUND This study was undertaken to investigate risk factors of mortality in patients with fulminant hepatic failure (FHF). METHODS Fifty-three patients with FHF treated from January 2006 to April 2011 were allocated to a spontaneous survival group (group 1), a death without liver transplantation (LT) group (group 2), and an LT group (group 3). To analyze risk factors associated with mortality in FHF, we excluded group 3 patients. Clinical features, Model for End-Stage Liver Disease (MELD) scores, and King's College Hospital criteria at the time of hepatic encephalopathy in group 2 were compared with those of group 1. RESULTS The causes of FHF were acute viral infection (n = 29, hepatitis A:B, 28:1), drugs (n = 18; including 4 acetaminophen and 14 herbal medication), autoimmune (n = 4), and miscellaneous (n = 2). Of the 53 patients, 19 were allocated to group 1, 18 to group 2, and 16 to group 3. According to univariate analysis, risk factors for mortality in group 2 were acute renal failure requiring renal replacement therapy and a MELD score ≥30 at the time of hepatic encephalopathy. However, by multivariate analysis, a MELD score ≥30 was the only independent risk factor for mortality in group 2 (P = .042; hazard ratio, 4.500). CONCLUSIONS A MELD score ≥30 was found to be the only independent risk factor of mortality in FHF patients without LT. Therefore, the findings of this study suggest that these patients may need emergent LT for survival.
Collapse
|
52
|
Lee JW, Kim HJ, Son BH, Ahn SH. Abstract P6-06-24: Intact p53 can predict more hormonal therapy benefit in invasive breast cancer: Evaluation of interactions between immunohistochemical p53 status and adjuvant therapy. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-06-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: To confirm the prognostic and predictive values of p53 accumulation, particularly in invasive breast cancer patients sorted according to subgroup based on immunohistochemical hormone receptor (HR) and HER2 status.
Methods: A total of 15,598 immunohistochemical data for p53, ER, PgR, and HER2 were retrospectively retrieved from the web-based database of the Korean Breast Cancer Society. Overall survival (OS) and breast cancer-specific survival (BCSS) were calculated and compared with the Kaplan-Meier method with log-rank test. Multivariate analyses were performed using a stratified Cox proportional hazard regression model. A model evaluating interactions between p53 and both hormonal therapy and chemotherapy was used to determine the treatment benefit from both modalities.
Results: Prognostic value of p53 was most significant in the HR+/HER2- subgroup for OS and BCSS, with hazard ratios of 1.44 (95% CI, 1.08-1.93) and of 1.47 (95% CI, 1.09-1.99). The hazard ratios for p53 overexpression had borderline significance in the HR+/HER2+, and were invalid in the HR-/HER2+ and HR-/HER2- subgroups. The model with interaction terms revealed that hormonal therapy significantly interacts with p53 status (p = .002 and .007 for OS and BCSS), resulting in an insignificant prognostic value of p53 status (p = .268 and .296 for OS and BCSS). An interaction between chemotherapy and p53 status was not found in this model.
Conclusion: p53 overexpression has independent prognostic value, particularly in the HR+/HER2- invasive breast cancer, which is most likely caused by differential treatment benefits from hormonal therapy depending on p53 status.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-24.
Collapse
|
53
|
Sohn G, Son BH, Baek S, Lee S, Lee Y, Kim HJ, Ko BS, Yu J, Lee JW, Ahn SH. Abstract P6-06-54: Analysis of treatment and survival of pathologic occult breast cancer with axillary lymph node metastasis: Nationwide retrospective study. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-06-54] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objective
Occult breast cancer (OBC) is a rare presentation which accounts for 0.3-1.0% of all breast cancers. In spite of limited information, there is no consensus regarding the prognostic factors and treatment of OBC. This retrospective study intends to evaluate the overall survival and prognostic factors of occult breast cancer (OBC) in Korea.
Method
This study included 142 pathologic occult breast cancer patients from January 1990 to December 2009, identified from Korean Breast Cancer Society cancer registry. All patients had pathologically positive axillary lymph node (N1-N3) along with pathologically & radiologically negative in-breast lesion (T0/Tx) based on retrospective review of database. Among 142 patients, 32 patients had only axillary lymph node dissection (ALND), 56 patients had breast conserving operation (BCO) with ALND and 54 patients had mastectomy with ALND. 96 patients (96%) had N1 disease, 23 patients (16.2%) had N2 disease and 23 patients (16.2%) had N3 disease.
Results
There was no significant statistical difference in overall survival among different operation method, which is ALND only, BCO with ALND, mastectomy with ALND (p = 0.061), considering that 12 patients (37.5%) among 32 patients who only had ALND had N3 disease comparing that only 7 (12.5%) out of 56 patients and 4 (7.4%) out of 54 patients had N3 disease in BCO with ALND and mastectomy with ALND group separately. Univariate analysis revealed that only nodal status was significant prognostic factor (p = 0.0004), and other factors including radiotherapy (p = 0.696), chemotherapy (p = 0.302), estrogen receptor positivity (p = 0.144), progesterone receptor positivity (p = 0.254), total number of removed lymph node (p = 0.586) didn't show statistical difference in overall survival.
Conclusions
This study suggests that OBC patients who only had ALND showed similar outcomes when comparing with patients who had BCO with ALND or mastectomy with ALND. Also only nodal status might be independent predictors for poor outcomes of occult breast cancer.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-54.
Collapse
|
54
|
Ahn SH, Lee SH, Kim BJ, Lim KH, Bae SJ, Kim EH, Kim HK, Choe JW, Koh JM, Kim GS. Higher serum uric acid is associated with higher bone mass, lower bone turnover, and lower prevalence of vertebral fracture in healthy postmenopausal women. Osteoporos Int 2013; 24:2961-70. [PMID: 23644878 DOI: 10.1007/s00198-013-2377-7] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2013] [Accepted: 04/19/2013] [Indexed: 12/13/2022]
Abstract
UNLABELLED Higher serum uric acid (UA) was associated with higher bone mass, lower bone turnover, and lower prevalence of vertebral fracture in postmenopausal women. Furthermore, UA suppressed osteoclastogenesis and decreased production of reactive oxygen species in osteoclast precursors, indicating UA may have beneficial effects on bone metabolism as an antioxidant. INTRODUCTION UA is known to play a physiological role as an antioxidant, and oxidative stress has detrimental effects on bone metabolism. In the present study, we investigated the association of serum UA level with the osteoporosis-related phenotypes and its direct effect on bone-resorbing osteoclasts using in vitro systems. METHODS This is a large cross-sectional study, including 7,502 healthy postmenopausal women. Bone mineral density (BMD) and serum UA concentrations were obtained from all subjects. Data on bone turnover markers and lateral thoracolumbar radiographs were available for 1,023 and 6,918 subjects, respectively. An in vitro study investigated osteoclastogenesis and reactive oxygen species (ROS) levels according to UA treatment. RESULTS After adjusting for multiple confounders, serum UA levels were positively associated with BMD at all sites (all p < 0.001). Compared with the participants in the highest UA quartile, the odds for osteoporosis were 40 % higher in those in the lowest quartile. The serum UA levels were inversely related to both serum C-terminal telopeptide of type I collagen and osteocalcin levels (p < 0.001 and p = 0.004, respectively). Consistently, subjects with vertebral fracture had lower serum UA levels, compared with those without it (p = 0.009). An in vitro study showed that UA decreased osteoclastogenesis in a dose-dependent manner and reduced the production of ROS in osteoclast precursors. CONCLUSION These results provide epidemiological and experimental evidence that serum UA may have a beneficial effect on bone metabolism as an antioxidant in postmenopausal women.
Collapse
|
55
|
Kim BJ, Ahn SH, Bae SJ, Kim EH, Kim TH, Lee SH, Kim HK, Choe JW, Kim SY, Koh JM, Kim GS. Association between metabolic syndrome and bone loss at various skeletal sites in postmenopausal women: a 3-year retrospective longitudinal study. Osteoporos Int 2013; 24:2243-52. [PMID: 23389696 DOI: 10.1007/s00198-013-2292-y] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/19/2012] [Accepted: 01/03/2013] [Indexed: 11/26/2022]
Abstract
UNLABELLED Although the presence of metabolic syndrome (MetS) and increasing numbers of MetS components were associated with attenuated bone loss at various skeletal sites in postmenopausal women, this beneficial effect of MetS on bone mass can be mainly explained by higher mechanical loading in the affected subjects. INTRODUCTION Previous cross-sectional epidemiological studies reported the inconsistent results regarding the combined effects of MetS on bone mass. In our present report, we performed a large, longitudinal study to evaluate MetS in relation to annualized bone mineral density (BMD) changes in postmenopausal Korean women. METHODS The study cohort consisted of 1,218 postmenopausal women who had undergone comprehensive routine health examinations with an average follow-up interval of 3 years. The BMD at the lumbar spine and proximal femur sites was measured with dual-energy X-ray absorptiometry using the same equipment at baseline and at follow-up. RESULTS Following adjustment for age, baseline BMD, and lifestyle factors, the women with MetS had 21.7, 17.0, 26.7, and 31.1 % less bone loss at the total femur, femur neck, trochanter, and lumbar spine, respectively, compared with MetS-free women (P = 0.004 to 0.041). Consistently, the rates of bone loss at all skeletal sites were linearly attenuated with increasing numbers of MetS components (P = 0.004 to <0.001). Importantly, when weight and height were added as confounding factors, the differences and trends of annualized BMD changes according to the MetS status disappeared. CONCLUSION Our current results indicate that the beneficial effects of MetS on bone mass can be mainly explained by higher mechanical loading in the affected subjects. Consequently, MetS per se may not be a meaningful concept for predicting future bone loss and for explaining associations between osteoporosis and cardiovascular diseases.
Collapse
|
56
|
Jo JC, Kang MJ, Ahn JH, Jung KH, Kim JE, Gong G, Kim HH, Ahn SD, Kim SS, Son BH, Ahn SH, Kim SB. Abstract P3-12-05: Clinical features and outcomes of leptomeningeal metastasis in patients with breast cancer: a single center experience. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-12-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Leptomeningeal metastasis (LM) is one of the major problems in managing metastatic breast cancer because of LM typically carries a devastating prognosis and often represents a terminal event. We analyzed the clinical features and outcomes of LM in patients with breast cancer.
Methods: We retrospectively reviewed the medical records of patients who were diagnosed with LM from breast cancer between 2002 and 2012 at Asan Medical Center.
Results: Of the 95 LM patients by cytologically proven (n = 81) or radiologically diagnosed (n = 14), 57 (60%) had an ECOG performance status (PS) ≥ 3, and the median age was 47 years (range, 26–72 years). The patients were diagnosed with LM after a median of 10.3 months (95% CI, 5.5–15.0 months) from the time of diagnosis of metastatic breast cancer. LM was present in 2 patients at the time of initial diagnosis. Twenty-three patients (24.2%) had isolated CNS metastasis, and 6 (6.3%) had only LM without any detectable metastasis sites. At the time of diagnosis of LM, 46 patients (48.4%) presented with coincidental failure of systemic disease control. Seventy-eight patients (82.1%) underwent intrathecal chemotherapy (methotrexate; n=78, thiotepa; n=11), resulting in one-third of cytologic negative conversion (n = 26), and 41 (43.2%) received systemic chemotherapy. The overall median survival time was 3.3 months (95% CI, 2.5–4.2 months) and 7.8% of the patients survived for more than 1 year. Overall survival tended to be better in patients who achieved cytologic negative conversion to intrathecal chemotherapy than those did not (median 4.5 months versus 3.2 months, P = 0.241). Overall survival was not different according to subtypes; hormone receptor (+), HER2 (+), and triple negative (median 3.6 months, 3.3 months, and 3.2 months, P = 0.937). Multivariate analysis demonstrated that ECOG PS ≥ 3 (HR = 2.09, 95% CI 1.21–3.58, P = 0.007), coincidental failure of systemic disease control at LM (HR = 3.01, 95% CI 1.76–5.15, P < 0.001), and systemic chemotherapy after LM (HR = 0.40, 95% CI 0.24–0.68, P = 0.001) were independent factors associated with survival.
Conclusions: The prognosis for patients with LM from breast cancer was still poor. Systemic chemotherapy in addition to intrathecal chemotherapy might confer a survival benefit, even after the detection of LM.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-12-05.
Collapse
|
57
|
Cho JY, Ahn SH, Lee JW, Yu JH, Koh BS, Kim HJ, Lee JW, Son BH, Gong GY, Kim HH. Abstract P3-01-02: Correlation of Mammographic breast density and tumor characteristics in Korean breast cancer patients. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Western studies have demonstrated high breast density as a strong risk factor for breast cancer, it is poorly understood whether breast density affects the diverse phenotypes of breast cancer. We examined the association between various tumor characteristics and mammographic breast density in women with breast cancer.
Methods: We conducted a cross-sectional analysis in 910 Korean women diagnosed with breast cancer to evaluate the associations between breast density and tumor size, lymph node status, lymphovascular invasion, histologic grade, estrogen receptor, progesterone receptor, HER2. Breast density was classified as fatty (percent density less than 50% by a computer-assisted thresholding program, named “Cumulus™”; n = 470) or dense (percent density 50% or more; n = 440) for the cancer-free breast at the time of operation. Logistic regression was used to examine whether the relationships were modified by adjustment for body mass index, age at diagnosis, age at first birth, menopausal status, history of breast-feeding, and breast cancer staging.
Results: Total 910 patients were involved, the mean age and median age at the operation was 48 years old (range 20–82), and the mean percent density was 48.09 (SD = 9.62 %: normally distributed, Kolmogorov-Smirnov test p = 0.32). Crude analysis shows that tumor size over than 0.5cm were more likely to have dense breasts compared with women with a tumor size <=0.5 cm (OR = 3.21, 95% CI = 1.59–6.45, p = 0.001 for tumor sizes 0.6–1.0cm; OR = 2.02, 95% CI = 1.09–3.74, p = 0.03 for tumor sizes 1.1–1.5cm; OR = 1.8, 95% CI = 0.97–3.33, p = 0.06 for tumor sizes 1.6–2.0cm; and OR = 1.64, 95% CI = 0.92–2.94, p = 0.1 for tumor sizes 2.1cm or more). PD and histologic grade shows reverse association between histologic grade 1 and grade 2,3. Progesteron receptor positive patients tend to have more dense(OR = 1.27, 95% CI=0.97–1.66, p = 0.07) breast than receptor negative patients, although after adjustment of age the statistical significant disappeared. Percent density was not significantly associated with, ER (p = 0.74), HER2 (p = 0.72).
Conclusion: These results suggest that breast density is associated with tumor size and histologic grade and progesterone receptor positivity. Additional studies are needed to address whether these associations are due to just density masking the detection of some tumors, biological causation, or both.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-01-02.
Collapse
|
58
|
Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Kim SU, Ahn SH, Chon CY, Han KH. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 35:1343-50. [PMID: 22486716 DOI: 10.1111/j.1365-2036.2012.05089.x] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2012] [Revised: 02/24/2012] [Accepted: 03/15/2012] [Indexed: 12/24/2022]
Abstract
BACKGROUND It remains unclear whether initial compact lipiodol uptake after transarterial chemoembolisation (TACE) is associated with improved survival in patients with hepatocellular carcinoma (HCC). AIM To reveal the clinical relevance of compact lipiodolisation after TACE. METHODS We studied 490 patients with unresectable HCC who had first been treated with TACE. Compact lipiodolisation was defined as the absence of an arterial enhancing lesion, reflecting complete lipiodol uptake, as assessed by dynamic computed tomography (CT) 1 month after treatment. The rate of initial compact lipiodolisation was analysed according to multiplicity and size of tumour, and survival of patients who achieved compact lipiodolisation was compared to that of patients who did not. RESULTS Of the 490 patients, 409 (83.5%) were in Child-Pugh class A and 81 (16.5%) in class B. The rate of initial compact lipiodolisation in single HCCs was higher than that in multinodular HCCs (33.7% vs. 14.6%, P < 0.001). Among single HCCs, the rate of compact lipiodolisation in tumours ≤5, 5-10 and >10 cm was 46.6%, 13.6%, and 0% respectively. The 1-, 3- and 5-year survival rates of patients with compact uptake were 92.7%, 70.7% and 52.4% compared to 60.8%, 28.0% and 16.9% in patients with noncompact lipiodolisation. Multivariate analysis revealed that Child-Pugh class, alpha-fetoprotein level, tumour node metastasis stage, portal vein thrombosis and initial compact lipiodolisation were independent predictors of survival. CONCLUSIONS Initial compact lipiodol uptake after transarterial chemoembolisation is associated with improved survival in patients with unresectable hepatocellular carcinoma. Accordingly, initial complete lipiodolisation should be considered a relevant therapeutic target.
Collapse
|
59
|
Schmitt KT, Jones KL, Bey A, Ahn SH, Bardayan DW, Blackmon JC, Brown SM, Chae KY, Chipps KA, Cizewski JA, Hahn KI, Kolata JJ, Kozub RL, Liang JF, Matei C, Matoš M, Matyas D, Moazen B, Nesaraja C, Nunes FM, O'Malley PD, Pain SD, Peters WA, Pittman ST, Roberts A, Shapira D, Shriner JF, Smith MS, Spassova I, Stracener DW, Villano AN, Wilson GL. Halo nucleus 11Be: a spectroscopic study via neutron transfer. PHYSICAL REVIEW LETTERS 2012; 108:192701. [PMID: 23003029 DOI: 10.1103/physrevlett.108.192701] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2012] [Indexed: 06/01/2023]
Abstract
The best examples of halo nuclei, exotic systems with a diffuse nuclear cloud surrounding a tightly bound core, are found in the light, neutron-rich region, where the halo neutrons experience only weak binding and a weak, or no, potential barrier. Modern direct-reaction measurement techniques provide powerful probes of the structure of exotic nuclei. Despite more than four decades of these studies on the benchmark one-neutron halo nucleus 11Be, the spectroscopic factors for the two bound states remain poorly constrained. In the present work, the 10Be(d,p) reaction has been used in inverse kinematics at four beam energies to study the structure of 11Be. The spectroscopic factors extracted using the adiabatic model were found to be consistent across the four measurements and were largely insensitive to the optical potential used. The extracted spectroscopic factor for a neutron in an nℓj=2s(1/2) state coupled to the ground state of 10Be is 0.71(5). For the first excited state at 0.32 MeV, a spectroscopic factor of 0.62(4) is found for the halo neutron in a 1p(1/2) state.
Collapse
|
60
|
Kim YH, Yang TY, Park CS, Ahn SH, Son BK, Kim JH, Lim DH, Jang TY. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 2012; 67:183-90. [PMID: 22050307 DOI: 10.1111/j.1398-9995.2011.02735.x] [Citation(s) in RCA: 85] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND Interleukin (IL)-33 is involved in the Th2 immune response and could play an essential role in nasal allergy. Therefore, we aimed to investigate the therapeutic potential of anti-IL-33 for allergic rhinitis (AR). METHODS Twenty-four BALB/c mice were used. In group A (control group, n = 6), mice were sensitized and challenged with saline. Group B [ovalbumin (OVA) group, n = 6] mice received intraperitoneal and intranasal OVA challenge. In group C (control IgG group, n = 6), mice were injected intraperitoneally with rabbit control IgG before OVA challenge. In group D (anti-IL-33 group, n = 6), anti-IL-33 was injected before challenge. We evaluated the number of nose-scratching events and external morphology; serum total and OVA-specific IgE; number of eosinophils, neutrophils, and lymphocytes in bronchoalveolar lavage (BAL) fluid; histopathologic examination of nasal cavity; and IL-4, IL-5, and IL-13 in BAL fluid. RESULTS Anti-IL-33 treatment significantly reduced the nose-scratching events and ameliorated skin denudation. Serum total and OVA-specific IgE was significantly decreased in group D. The number of eosinophils in BAL fluid was also significantly decreased. Eosinophilic infiltration in the nasal cavity was significantly decreased in group D. IL-4, IL-5, and IL-13 in BAL fluid were also significantly decreased after treatment. CONCLUSIONS Anti-IL-33 antibody has a therapeutic potential for experimental AR.
Collapse
|
61
|
Byun WM, Ahn SH, Ahn MW. Value of 3D MR lumbosacral radiculography in the diagnosis of symptomatic chemical radiculitis. AJNR Am J Neuroradiol 2011; 33:529-34. [PMID: 22194385 DOI: 10.3174/ajnr.a2813] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Radiologic methods for the diagnosis of chemical radiculitis associated with anular tears in the lumbar spine have been rare. Provocative diskography is one of the methods for diagnosing diskogenic chemical radiculitis but is invasive. A reliable imaging method for replacing provocative diskography and diagnosing chemical radiculitis is required. Our aim was to investigate the value of 3D MR radiculography depicted by rendering imaging in the diagnosis of symptomatic chemical radiculopathy associated with anular tears. MATERIALS AND METHODS The study population consisted of 17 patients (age range, 32-88 years) with unilateral radiculopathy. Symptomatic chemical radiculopathy was confirmed with provocative CT diskography and/or provocative selective nerve root block for agreement of sides and levels. Through adhering to the principles of selective excitation (Proset imaging), we acquired 3D coronal FFE sequences with selective water excitation. Morphologic changes in the ipsilateral symptomatic nerve root caused by chemical radiculopathy were compared with those in the contralateral nerve root on 3D MR lumbosacral radiculography. RESULTS Pain reproduction at the contrast-leak level during diskography (n = 4) and selective nerve root injection (n = 13) showed concordant pain in all patients. All patients with symptomatic chemical radiculopathy showed nerve root swelling in both ipsilateral levels and sides on 3D MR radiculography. The most common nerve root affected by the chemical radiculopathy was the L5 nerve root (n = 13), while the most common segment exhibiting nerve root swelling was the exit nerve root (n = 16). CONCLUSIONS All patients with radicular leg pain caused by chemical radiculopathy showed nerve root swelling on 3D MR radiculography. We believe that in cases without mechanical nerve root compression caused by disk herniation or stenosis in the lumbar spine, nerve root swelling on 3D MR radiculography in patients with radiculopathy associated with an anular tear may be relevant in the diagnosis of symptomatic chemical radiculopathy.
Collapse
|
62
|
Kim HJ, Yi OV, Koh BS, Yu JH, Lee JW, Son BH, Ahn SH. P3-09-06: Changes of Serum Vitamin D According to the Breast Cancer Treatment. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-09-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Vitamin D deficiency is associated with increased breast cancer risk and decreased breast cancer survival. The purpose of this study was to determine the effect of breast cancer adjuvant treatment to the vitamin D status, as measured by the serum hydroxyvitamin D (25OHD) in breast cancer patients.
Patients and Methods: For 589 patients who was diagnosed as a non metastatic breast cancer in 2009 at the asan medical center, blood was prospectively analyzed in batches for serum 25 OHD level at basal and at 6 and 12month. We excluded the patients who took a vitamin D supplementation and got a neoadjuvant chemotherapy. Vitamin D sufficiency was defined as serum as 30ng/ml or greater, insufficiency as 20 to 29 ng/ml and insufficiency as less than 20ng/ml.
Results: At baseline, mean serum 25OHD was greater in summer (April to Oct) than Winter(Nov to May) (28.2ng/ml vs 32.9ng/ml respectively, p=0.000). The patients who did not get a chemotherapy and antihormonal therapy as baseline, the patient with chemotherapy showed decreased serum 25OHD level than who without chemotherapy in 6 month but not in 12 month (p=0.003, vs p=0.156 respectively). The patients who had taken anti-hormonal therapy showed significant increasing serum 25OHD in 6 month and 12 months (p=0.000 both). For the patients who got both chemotherapy and anti-hormonal therapy, the changes of serum 25OHD level is smaller than the patients who got a chemotherapy only.
For the patients who got a chemotherapy, 57% of patients were vitamin D sufficient at baseline, but 27% of patients in 6 month and 49% in 12 month (p=0.001).
Conclusion: Vitamin D status was worsen during chemotherapy but recovered after chemotherapy. Anti hormonal therapy make the serum vitamin D level increased. The translational research about the effect of chemotherapy and anti-hormonal therapy to the vitamin D status should be warranted.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-09-06.
Collapse
|
63
|
Koo DH, Ahn JH, Yoon DH, Kim SB, Lee HJ, Kong KY, Son BH, Ahn SH, Jung KH. P5-13-11: PTEN and Tau-Protein Expression: Predictive Value of Poor Response to Trastuzumab Plus Paclitaxel in Patients with HER2−Positive Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-13-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Backgrounds: Trastuzumab-based chemotherapy has been an active treatment in patients (pts) with HER2−positive breast cancer; however, primary and secondary resistance has occurred in pts treated with trastuzumab (H) alone or in combination with chemotherapy. Material and Methods: Biomarkers were searched using tissue microarrays (TMA) in the HER2−positive breast cancer pts treated with H and paclitaxel (P) combination chemotherapy between October 2004 and August 2010. Tumor blocks of 101 pts were analyzed for VEGF, IGF-1R, p-Akt, beta-III tubulin, CD44, Tau-protein, p27 and PTEN by immunohistochemical (IHC) analysis. Eight biomarkers were assessed to investigate the correlation with the clinical outcomes, including response rate (RR), progression free survival (PFS), and overall survival (OS).
Results: With a median follow-up duration of 21.7 months (range, 9.1−55.2 months), 101 pts received H+P chemotherapy in neoadjuvant setting (n=36, 35.6%) and recurrent or metastatic setting (n=65, 64.4%). Median age was 48 (range, 19–83 years), and the majority of pts (n=95, 94.1%) had good performance status. Premenopausal pts and hormone receptor-negative pts were 48 (47.5%) and 52 (51.5%), respectively. The median cycle of H+P chemotherapy was six (range, H 1–43; P 1–21). Overall RR was 68.3% (n=69) including complete response with 7 pts, and PFS and OS were significantly longer in pts responsive to H+P chemotherapy compared with non-responsive patients (PFS, p=0.001; OS, p=0.015). Although VEGF, IGF-1R, p-Akt, beta-III tubulin, CD44, p27 and PTEN status by IHC were not significantly associated with response to H+P chemotherapy, Tau-protein showed a trend of association without statistical significance (RR, 46.2% vs. 71.6%, p=0.066). Among 13 pts with high Tau protein expression, 9 pts with both high Tau-protein and low PTEN level showed statistically significant lower RR compared with other 92 pts (22.2% vs. 72.8%; p=0.002). None of the biomarkers was related to PFS and OS in pts with recurrent or metastatic disease, and to pathologic complete response in pts after H+P chemotherapy as neoadjuvant therapy.
Conclusion: Our data showed that both low PTEN level and high Tauprotein expression were significantly associated with poor response to H+P chemotherapy in patients with HER2−positive breast cancer.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-13-11.
Collapse
|
64
|
Shin HJ, Kim HH, Ahn JH, Kim SB, Jung KH, Gong G, Son BH, Ahn SH. Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy. Br J Radiol 2010; 84:612-20. [PMID: 21081579 DOI: 10.1259/bjr/74430952] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
OBJECTIVES The purpose of this study was to determine the relative accuracies of mammography, sonography, MRI and clinical examination in predicting residual tumour size and pathological response after neoadjuvant chemotherapy for locally advanced or inflammatory breast cancer. Each prediction method was compared with the gold standard of surgical pathology. METHODS 43 patients (age range, 25-62 years; mean age, 42.7 years) with locally advanced or inflammatory breast cancer who had been treated by neoadjuvant chemotherapy were enrolled prospectively. We compared the predicted residual tumour size and the predicted response on imaging and clinical examination with residual tumour size and response on pathology. Statistical analysis was performed using weighted kappa statistics and intraclass correlation coefficients (ICC). RESULTS The ICC values between predicted tumour size and pathologically determined tumour size were 0.65 for clinical examination, 0.69 for mammography, 0.78 for sonography and 0.97 for MRI. Agreement between the response predictions at mid-treatment and the responses measured by pathology had kappa values of 0.28 for clinical examination, 0.32 for mammography, 0.46 for sonography and 0.68 for MRI. Agreement between the final response predictions and the responses measured by pathology had kappa values of 0.43 for clinical examination, 0.44 for mammography, 0.50 for sonography and 0.82 for MRI. CONCLUSION Predictions of response and residual tumour size made on MRI were better correlated with the assessments of response and residual tumour size made upon pathology than were predictions made on the basis of clinical examination, mammography or sonography. Thus, the evaluation of predicted response using MRI could provide a relatively sensitive early assessment of chemotherapy efficacy.
Collapse
|
65
|
Shin HJ, Kim HH, Huh MO, Kim MJ, Yi A, Kim H, Son BH, Ahn SH. Correlation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive breast cancer. Br J Radiol 2010; 84:19-30. [PMID: 20682592 DOI: 10.1259/bjr/92960562] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVES The purpose of this study was to correlate sonographic and mammographic findings with prognostic factors in patients with node-negative invasive breast cancer. METHODS Sonographic and mammographic findings in 710 consecutive patients (age range 21-81 years; mean age 49 years) with 715 node-negative invasive breast cancers were retrospectively evaluated. Pathology reports relating to tumour size, histological grade, lymphovascular invasion (LVI), extensive intraductal component (EIC), oestrogen receptor (ER) status and HER-2/neu status were reviewed and correlated with the imaging findings. Statistical analysis was performed using logistic regression analysis and intraclass correlation coefficient (ICC). RESULTS On mammography, non-spiculated masses with calcifications were associated with all poor prognostic factors: high histological grade, positive LVI, EIC, HER-2/neu status and negative ER. Other lesions were associated with none of these poor prognostic factors. Hyperdense masses on mammography, the presence of mixed echogenicity, posterior enhancement, calcifications in-or-out of masses and diffusely increased vascularity on sonography were associated with high histological grade and negative ER. Associated calcifications on both mammograms and sonograms were correlated with EIC and HER-2/neu overexpression. The ICC value for the disease extent was 0.60 on mammography and 0.70 on sonography. CONCLUSION Several sonographic and mammographic features can have a prognostic value in the subsequent treatment of patients with node-negative invasive breast cancer. Radiologists should pay more attention to masses that are associated with calcifications because on both mammography and sonography associated calcifications were predictors of positive EIC and HER-2/neu overexpression.
Collapse
|
66
|
Kim SU, Seo YS, Cheong JY, Kim MY, Kim JK, Um SH, Cho SW, Paik SK, Lee KS, Han KH, Ahn SH. Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B. Aliment Pharmacol Ther 2010; 32:498-505. [PMID: 20491742 DOI: 10.1111/j.1365-2036.2010.04353.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND Interquartile range/median value (IQR/M) of liver stiffness measurement (LSM) is a factor in chronic hepatitis C (CHC) leading to over estimation of fibrosis by Fibroscan. AIM To investigate factors that affect the accuracy of LSM in chronic hepatitis B (CHB). METHODS One hundred and ninety-nine patients were enrolled. Only procedures yielding > or =10 valid measurements were considered reliable. Liver fibrosis was evaluated using the Batts and Ludwig system. Liver biopsy (LB) specimens <15 mm were considered ineligible. RESULTS The mean age (142 men and 57 women) was 40.1 years. A significant discordance (discordance of at least two stages between LB and LSM) was identified in 38 (19.1%) and 47 (23.6%) patients respectively, according to Marcellin et al. and Chan et al.'s cutoff values. In multivariate analyses, BMI and fibrosis stage (F0-2 vs. F3-4) were identified as independent predictors for significant discordance (P = 0.040; hazard ratio [HR], 1.126; 95% confidence interval [CI], 1.005-1.261 and P = 0.036; HR, 0.450; 95% CI, 0.213-0.949 respectively) with Marcellin et al.'s cutoffs, whereas fibrosis stage was the only independent predictor (P = 0.004; HR, 0.300; 95% CI, 0.131-0.685) with Chan's cutoffs. CONCLUSIONS Success rate and IQR/M were not predictive factors of the accuracy for diagnosing liver fibrosis by Fibroscan in CHB. Fibrosis stage (F0-2) was the only factor to predict significant discordance between LB and LSM.
Collapse
|
67
|
Chang MC, Ahn SH, Byeon WM, Jang SH. Corticospinal Tract Location at the Upper Pons in the Human Brain. Neuroimage 2009. [DOI: 10.1016/s1053-8119(09)71221-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
68
|
Kwak SY, Jang SH, Kim SH, Kim OR, Byeon WM, Ahn SH. Title: Corticospinal Tract Injury in Patients with Diffuse Axonal Injury: A Diffusion Tensor Imaging Study. Neuroimage 2009. [DOI: 10.1016/s1053-8119(09)71533-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
69
|
Jang SH, Ahn SH, Byun WM, Kim C, Kwon YH. Enhanced Neural Activation after Transcranial Direct Current Stimulation on Primary Sensoriomotor Cortex in the Human Brain: An fMRI study. Neuroimage 2009. [DOI: 10.1016/s1053-8119(09)71209-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
70
|
Lim YK, Kwak JW, Kim DW, Shin DH, Yoon MG, Ahn SH, Park SA, Lee DH, Lee SB, Park SY, Kim DY. SU-FF-J-71: A Prototype Fiducial Marker Composed of Gold Nanoparticles and Bone Cement for Proton Therapy of Prostate Cancers. Med Phys 2009. [DOI: 10.1118/1.3181363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
71
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams M, Adams T, Aguilo E, Ahn SH, Ahsan M, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Ancu LS, Andeen T, Anderson S, Andrieu B, Anzelc MS, Aoki M, Arnoud Y, Arov M, Arthaud M, Askew A, Asman B, Assis Jesus ACS, Atramentov O, Avila C, Badaud F, Baden A, Bagby L, Baldin B, Bandurin DV, Banerjee P, Banerjee S, Barberis E, Barfuss AF, Bargassa P, Baringer P, Barreto J, Bartlett JF, Bassler U, Bauer D, Beale S, Bean A, Begalli M, Begel M, Belanger-Champagne C, Bellantoni L, Bellavance A, Benitez JA, Beri SB, Bernardi G, Bernhard R, Bertram I, Besançon M, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Biscarat C, Blazey G, Blekman F, Blessing S, Bloch D, Bloom K, Boehnlein A, Boline D, Bolton TA, Boos EE, Borissov G, Bose T, Brandt A, Brock R, Brooijmans G, Bross A, Brown D, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Bunichev V, Burdin S, Burke S, Burnett TH, Buszello CP, Butler JM, Calfayan P, Calvet S, Cammin J, Carvalho W, Casey BCK, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan K, Chan KM, Chandra A, Charles F, Cheu E, Chevallier F, Cho DK, Choi S, Choudhary B, Christofek L, Christoudias T, Cihangir S, Claes D, Clutter J, Cooke M, Cooper WE, Corcoran M, Couderc F, Cousinou MC, Crépé-Renaudin S, Cutts D, Cwiok M, da Motta H, Das A, Davies G, De K, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Degenhardt JD, Déliot F, Demarteau M, Demina R, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Dominguez A, Dong H, Dudko LV, Duflot L, Dugad SR, Duggan D, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Ellison J, Elvira VD, Enari Y, Eno S, Ermolov P, Evans H, Evdokimov A, Evdokimov VN, Ferapontov AV, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Fortner M, Fox H, Fu S, Fuess S, Gadfort T, Galea CF, Gallas E, Garcia C, Garcia-Bellido A, Gavrilov V, Gay P, Geist W, Gelé D, Gerber CE, Gershtein Y, Gillberg D, Ginther G, Gollub N, Gómez B, Goussiou A, Grannis PD, Greenlee H, Greenwood ZD, Gregores EM, Grenier G, Gris P, Grivaz JF, Grohsjean A, Grünendahl S, Grünewald MW, Guo F, Guo J, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haefner P, Hagopian S, Haley J, Hall I, Hall RE, Han L, Harder K, Harel A, Hauptman JM, Hauser R, Hays J, Hebbeker T, Hedin D, Hegeman JG, Heinson AP, Heintz U, Hensel C, Herner K, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hoeth H, Hohlfeld M, Hong SJ, Hossain S, Houben P, Hu Y, Hubacek Z, Hynek V, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jakobs K, Jarvis C, Jesik R, Johns K, Johnson C, Johnson M, Jonckheere A, Jonsson P, Juste A, Kajfasz E, Kalk JM, Karmanov D, Kasper PA, Katsanos I, Kau D, Kaushik V, Kehoe R, Kermiche S, Khalatyan N, Khanov A, Kharchilava A, Kharzheev YM, Khatidze D, Kim TJ, Kirby MH, Kirsch M, Klima B, Kohli JM, Konrath JP, Kozelov AV, Kraus J, Krop D, Kuhl T, Kumar A, Kupco A, Kurca T, Kuzmin VA, Kvita J, Lacroix F, Lam D, Lammers S, Landsberg G, Lebrun P, Lee WM, Leflat A, Lellouch J, Leveque J, Li J, Li L, Li QZ, Lietti SM, Lima JGR, Lincoln D, Linnemann J, Lipaev VV, Lipton R, Liu Y, Liu Z, Lobodenko A, Lokajicek M, Love P, Lubatti HJ, Luna R, Lyon AL, Maciel AKA, Mackin D, Madaras RJ, Mättig P, Magass C, Magerkurth A, Mal PK, Malbouisson HB, Malik S, Malyshev VL, Mao HS, Maravin Y, Martin B, McCarthy R, Melnitchouk A, Mendoza L, Mercadante PG, Merkin M, Merritt KW, Meyer A, Meyer J, Millet T, Mitrevski J, Mommsen RK, Mondal NK, Moore RW, Moulik T, Muanza GS, Mulhearn M, Mundal O, Mundim L, Nagy E, Naimuddin M, Narain M, Naumann NA, Neal HA, Negret JP, Neustroev P, Nilsen H, Nogima H, Novaes SF, Nunnemann T, O'Dell V, O'Neil DC, Obrant G, Ochando C, Onoprienko D, Oshima N, Osman N, Osta J, Otec R, Otero y Garzón GJ, Owen M, Padley P, Pangilinan M, Parashar N, Park SJ, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Pawloski G, Penning B, Perfilov M, Peters K, Peters Y, Pétroff P, Petteni M, Piegaia R, Piper J, Pleier MA, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pol ME, Polozov P, Pope BG, Popov AV, Potter C, Prado da Silva WL, Prosper HB, Protopopescu S, Qian J, Quadt A, Quinn B, Rakitine A, Rangel MS, Ranjan K, Ratoff PN, Renkel P, Reucroft S, Rich P, Rieger J, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Robinson S, Rodrigues RF, Rominsky M, Royon C, Rubinov P, Ruchti R, Safronov G, Sajot G, Sánchez-Hernández A, Sanders MP, Sanghi B, Santoro A, Savage G, Sawyer L, Scanlon T, Schaile D, Schamberger RD, Scheglov Y, Schellman H, Schliephake T, Schwanenberger C, Schwartzman A, Schwienhorst R, Sekaric J, Severini H, Shabalina E, Shamim M, Shary V, Shchukin AA, Shivpuri RK, Siccardi V, Simak V, Sirotenko V, Skubic P, Slattery P, Smirnov D, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Sonnenschein L, Sopczak A, Sosebee M, Soustruznik K, Spurlock B, Stark J, Steele J, Stolin V, Stoyanova DA, Strandberg J, Strandberg S, Strang MA, Strauss E, Strauss M, Ströhmer R, Strom D, Stutte L, Sumowidagdo S, Svoisky P, Sznajder A, Tamburello P, Tanasijczuk A, Taylor W, Temple J, Tiller B, Tissandier F, Titov M, Tokmenin VV, Toole T, Torchiani I, Trefzger T, Tsybychev D, Tuchming B, Tully C, Tuts PM, Unalan R, Uvarov L, Uvarov S, Uzunyan S, Vachon B, van den Berg PJ, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vint P, Vokac P, Von Toerne E, Voutilainen M, Wagner R, Wahl HD, Wang L, Wang MHLS, Warchol J, Watts G, Wayne M, Weber G, Weber M, Welty-Rieger L, Wenger A, Wermes N, Wetstein M, White A, Wicke D, Wilson GW, Wimpenny SJ, Wobisch M, Wood DR, Wyatt TR, Xie Y, Yacoob S, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yip K, Yoo HD, Youn SW, Yu J, Zeitnitz C, Zhao T, Zhou B, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zivkovic L, Zutshi V, Zverev EG. Measurement of the lifetime of the Bc+/- meson in the semileptonic decay channel. PHYSICAL REVIEW LETTERS 2009; 102:092001. [PMID: 19392512 DOI: 10.1103/physrevlett.102.092001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/19/2008] [Indexed: 05/27/2023]
Abstract
Using approximately 1.3 fb(-1) of data collected by the D0 detector between 2002 and 2006, we measure the lifetime of the Bc+/- meson in the Bc-/+-->J/psimicro+/-+X final state. A simultaneous unbinned likelihood fit to the J/psi+micro invariant mass and lifetime distributions yields a signal of 881+/-80(stat) candidates and a lifetime measurement of tau(Bc+/-)=0.448(-0.036)(+0.038)(stat)+/-0.032(syst) ps.
Collapse
|
72
|
Kim HJ, Lee JS, Park EH, Lim WS, Sei JY, Koh BS, Son BH, Ahn JH, Jeong KH, Kim SB, Ahn SH. Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea. Eur J Surg Oncol 2009; 35:936-41. [PMID: 19269125 DOI: 10.1016/j.ejso.2009.01.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2008] [Revised: 01/23/2009] [Accepted: 01/28/2009] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Hormone receptor-positive, pre-menopausal breast cancer patients can be treated by chemotherapy and/or ovarian suppression therapy. We reported our experience of gonadotropin-releasing hormone analogue plus tamoxifen (GnRHa+T) or adriamycin and cyclophosphamide (AC) followed by tamoxifen (AC-->T) in pre-menopausal women with hormone-response, node-negative breast cancer. METHODS We retrospectively reviewed the records of 587 pre-menopausal women with hormone-responsive, node-negative breast cancer. Of these, 269 were treated with adriamycin and cyclophosphamide (AC) followed by tamoxifen (AC-->T), and 318 were treated with gonadotropin-releasing hormone analogue plus tamoxifen (GnRHa+T). Among them, 151 patients were treated by goserelin acetate 3.6 mg/kg and 125 patients were treated by leuprorelin acetate 3.75 mg/kg every 28 days subcutaneously. FINDINGS At a median follow-up time of 30 months, eight patients had relapsed and three had died. DFS did not differ between the AC-->T and GnRHa+T groups. Of the three deaths, two were not related to breast cancer. The third patient, in the AC-->T group, died because of brain metastasis. GnRHa+T treatment had no effect on blood profile and did not cause the development of detrimental symptoms but decreased bone mineral density. The efficacy of leuprorelin was similar to that of goserelin. INTERPRETATION GnRHa+T treatment can be an alternative treatment option in pre-menopausal women with endocrine-responsive, node-negative, breast cancer patients. The efficacy and tolerability of leuprorelin were similar to that of goserelin.
Collapse
|
73
|
Choi YH, Ahn JH, Kim SB, Jung KH, Gong GY, Kim MJ, Son BH, Ahn SH, Kim WK. Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Ann Oncol 2009; 20:1337-43. [PMID: 19221151 DOI: 10.1093/annonc/mdp003] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
BACKGROUND Despite good prognosis in most cases of lymph node (LN)-negative breast cancer, individual patients may have markedly different clinical outcomes. Here, we investigated the prognostic significance of HER2/neu overexpression in these tumors. MATERIALS AND METHODS We employed a tissue microarray to examine HER2/neu overexpression by immunohistochemical staining in 359 consecutive patients diagnosed with LN-negative breast cancer, who underwent surgery from January 1993 to December 1998. RESULTS HER2/neu overexpression was detected in 81 of 359 (23.1%) patients. The 10-year disease-free survival (DFS) values (81.2% versus 61.8%, P value 0.000) and overall survival (OS) rates (85.7% versus 63.9%, P value 0.000) were significantly different between cases with HER2/neu-negative or HER2/neu-positive tumors. After multivariate analysis, HER2/neu status and tumor size were identified as independent prognostic factors for 10-year OS. Moreover, HER2/neu overexpression was significantly associated with poorer clinical outcomes in an intermediate-risk group identified by the St Gallen classification (10-year DFS, 79.6% versus 61.8%, P value 0.000; 10-year OS, 84.7% versus 63.9%, P value 0.000). CONCLUSIONS Our results show that HER2/neu overexpression is an important independent prognostic factor for LN-negative breast cancer cases and support the theory that more intensive adjuvant chemotherapy is required in the population with HER2/neu overexpression.
Collapse
|
74
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams M, Adams T, Aguilo E, Ahn SH, Ahsan M, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Ancu LS, Andeen T, Anderson S, Andrieu B, Anzelc MS, Arnoud Y, Arov M, Arthaud M, Askew A, Asman B, Assis Jesus ACS, Atramentov O, Autermann C, Avila C, Ay C, Badaud F, Baden A, Bagby L, Baldin B, Bandurin DV, Banerjee S, Banerjee P, Barberis E, Barfuss AF, Bargassa P, Baringer P, Barreto J, Bartlett JF, Bassler U, Bauer D, Beale S, Bean A, Begalli M, Begel M, Belanger-Champagne C, Bellantoni L, Bellavance A, Benitez JA, Beri SB, Bernardi G, Bernhard R, Bertram I, Besançon M, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Biscarat C, Blazey G, Blekman F, Blessing S, Bloch D, Bloom K, Boehnlein A, Boline D, Bolton TA, Borissov G, Bose T, Brandt A, Brock R, Brooijmans G, Bross A, Brown D, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Bunichev S, Burdin S, Burke S, Burnett TH, Buszello CP, Butler JM, Calfayan P, Calvet S, Cammin J, Carvalho W, Casey BCK, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chan K, Chandra A, Charles F, Cheu E, Chevallier F, Cho DK, Choi S, Choudhary B, Christofek L, Christoudias T, Cihangir S, Claes D, Coadou Y, Cooke M, Cooper WE, Corcoran M, Couderc F, Cousinou MC, Crépé-Renaudin S, Cutts D, Cwiok M, da Motta H, Das A, Davies G, De K, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Degenhardt JD, Déliot F, Demarteau M, Demina R, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Dominguez A, Dong H, Dudko LV, Duflot L, Dugad SR, Duggan D, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Ellison J, Elvira VD, Enari Y, Eno S, Ermolov P, Evans H, Evdokimov A, Evdokimov VN, Ferapontov AV, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Ford M, Fortner M, Fox H, Fu S, Fuess S, Gadfort T, Galea CF, Gallas E, Galyaev E, Garcia C, Garcia-Bellido A, Gavrilov V, Gay P, Geist W, Gelé D, Gerber CE, Gershtein Y, Gillberg D, Ginther G, Gollub N, Gómez B, Goussiou A, Grannis PD, Greenlee H, Greenwood ZD, Gregores EM, Grenier G, Gris P, Grivaz JF, Grohsjean A, Grüendahl S, Grünewald MW, Guo J, Guo F, Gutierrez P, Gutierrez G, Haas A, Hadley NJ, Haefner P, Hagopian S, Haley J, Hall I, Hall RE, Han L, Hansson P, Harder K, Harel A, Harrington R, Hauptman JM, Hauser R, Hays J, Hebbeker T, Hedin D, Hegeman JG, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Herner K, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hoeth H, Hohlfeld M, Hong SJ, Hossain S, Houben P, Hu Y, Hubacek Z, Hynek V, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jakobs K, Jarvis C, Jesik R, Johns K, Johnson C, Johnson M, Jonckheere A, Jonsson P, Juste A, Kajfasz E, Kalinin AM, Kalk JR, Kalk JM, Kappler S, Karmanov D, Kasper PA, Katsanos I, Kau D, Kaur R, Kaushik V, Kehoe R, Kermiche S, Khalatyan N, Khanov A, Kharchilava A, Kharzheev YM, Khatidze D, Kim TJ, Kirby MH, Kirsch M, Klima B, Kohli JM, Konrath JP, Korablev VM, Kozelov AV, Krop D, Kuhl T, Kumar A, Kunori S, Kupco A, Kurca T, Kvita J, Lacroix F, Lam D, Lammers S, Landsberg G, Lebrun P, Lee WM, Leflat A, Lehner F, Lellouch J, Leveque J, Li J, Li QZ, Li L, Lietti SM, Lima JGR, Lincoln D, Linnemann J, Lipaev VV, Lipton R, Liu Y, Liu Z, Lobodenko A, Lokajicek M, Love P, Lubatti HJ, Luna R, Lyon AL, Maciel AKA, Mackin D, Madaras RJ, Mättig P, Magass C, Magerkurth A, Mal PK, Malbouisson HB, Malik S, Malyshev VL, Mao HS, Maravin Y, Martin B, McCarthy R, Melnitchouk A, Mendoza L, Mercadante PG, Merkin M, Merritt KW, Meyer J, Meyer A, Millet T, Mitrevski J, Molina J, Mommsen RK, Mondal NK, Moore RW, Moulik T, Muanza GS, Mulders M, Mulhearn M, Mundal O, Mundim L, Nagy E, Naimuddin M, Narain M, Naumann NA, Neal HA, Negret JP, Neustroev P, Nilsen H, Nogima H, Novaes SF, Nunnemann T, O'Dell V, O'Neil DC, Obrant G, Ochando C, Onoprienko D, Oshima N, Osta J, Otec R, Otero Y Garzón GJ, Owen M, Padley P, Pangilinan M, Parashar N, Park SJ, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Pawloski G, Penning B, Perfilov M, Peters K, Peters Y, Pétroff P, Petteni M, Piegaia R, Piper J, Pleier MA, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pol ME, Polozov P, Pope BG, Popov AV, Potter C, Prado da Silva WL, Prosper HB, Protopopescu S, Qian J, Quadt A, Quinn B, Rakitine A, Rangel MS, Ranjan K, Ratoff PN, Renkel P, Reucroft S, Rich P, Rieger J, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Robinson S, Rodrigues RF, Rominsky M, Royon C, Rubinov P, Ruchti R, Safronov G, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schaile D, Schamberger RD, Scheglov Y, Schellman H, Schliephake T, Schwanenberger C, Schwartzman A, Schwienhorst R, Sekaric J, Severini H, Shabalina E, Shamim M, Shary V, Shchukin AA, Shivpuri RK, Siccardi V, Simak V, Sirotenko V, Skubic P, Slattery P, Smirnov D, Snow J, Snow GR, Snyder S, Söldner-Rembold S, Sonnenschein L, Sopczak A, Sosebee M, Soustruznik K, Spurlock B, Stark J, Steele J, Stolin V, Stoyanova DA, Strandberg J, Strandberg S, Strang MA, Strauss M, Strauss E, Ströhmer R, Strom D, Stutte L, Sumowidagdo S, Svoisky P, Sznajder A, Talby M, Tamburello P, Tanasijczuk A, Taylor W, Temple J, Tiller B, Tissandier F, Titov M, Tokmenin VV, Toole T, Torchiani I, Trefzger T, Tsybychev D, Tuchming B, Tully C, Tuts PM, Unalan R, Uvarov S, Uvarov L, Uzunyan S, Vachon B, van den Berg PJ, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vint P, Vokac P, Von Toerne E, Voutilainen M, Wagner R, Wahl HD, Wang L, Wang MHLS, Warchol J, Watts G, Wayne M, Weber M, Weber G, Welty-Rieger L, Wenger A, Wermes N, Wetstein M, White A, Wicke D, Wilson GW, Wimpenny SJ, Wobisch M, Wood DR, Wyatt TR, Xie Y, Yacoob S, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yip K, Yoo HD, Youn SW, Yu J, Zatserklyaniy A, Zeitnitz C, Zhao T, Zhou B, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zivkovic L, Zutshi V, Zverev EG. Measurement of the semileptonic branching ratio of B_{s};{0} to an orbitally excited D_{s};{**} state: Br(B_{s};{0}-->D_{s1};{-}(2536)mu;{+}nuX). PHYSICAL REVIEW LETTERS 2009; 102:051801. [PMID: 19257502 DOI: 10.1103/physrevlett.102.051801] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/26/2007] [Indexed: 05/27/2023]
Abstract
In a data sample of approximately 1.3 fb;{-1} collected with the D0 detector between 2002 and 2006, the orbitally excited charm state D_{s1};{+/-}(2536) has been observed with a measured mass of 2535.7+/-0.6(stat)+/-0.5(syst) MeV/c;{2} via the decay mode B_{s};{0}-->D_{s1};{-}(2536)mu;{+}nu_{mu}X. A first measurement is made of the branching ratio product Br(b[over ]-->D_{s1};{-}(2536)mu;{+}nu_{mu}X)xBr(D_{s1};{-}-->D;{*-}K_{S};{0}). Assuming that D_{s1};{-}(2536) production in semileptonic decay is entirely from B_{s};{0}, an extraction of the semileptonic branching ratio Br(B_{s};{0}-->D_{s1};{-}(2536)mu;{+}nu_{mu}X) is made.
Collapse
|
75
|
Jayaraman MV, Chang H, Ahn SH. An easily identifiable anatomic landmark for fluoroscopically guided sacroplasty: anatomic description and validation with treatment in 13 patients. AJNR Am J Neuroradiol 2009; 30:1070-3. [PMID: 19193750 DOI: 10.3174/ajnr.a1502] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Percutaneous sacroplasty has recently gained attention as a potential treatment for sacral insufficiency fractures. We describe a readily identifiable fluoroscopic landmark that facilitates needle placement and validate this with virtual needle placement by using CT data and fluoroscopically guided treatment in 13 patients. MATERIALS AND METHODS From CTs of 100 consecutive patients, the optimal target zone for needle placement in the sacral ala was defined at the intersection of lines from each of the corners of the first sacral segment, which is readily identifiable on lateral fluoroscopy. We then measured the distance from that virtual target point to the anterior sacral cortex by using the CT data for 3 specific trajectories: 1) parallel to the L5-S1 disk, 2) axial with respect to the patient, and 3) along the long axis of the sacrum. Case records of 13 consecutive patients treated by using this technique were also reviewed. RESULTS The mean distances for the 3 trajectories were 11.3 mm, 11.2 mm, and 12.8 mm, respectively. Needle placement would have been outside the anterior sacral cortex in 3 patients. Review of preprocedure imaging easily identified this potential breach. During treatment, needle placement by using the landmark was successful in all patients, and there were no complications. CONCLUSIONS A safe target for sacroplasty needle placement in the superolateral sacral ala can be defined by using the intersection of lines drawn from the corners of the first sacral segment. We validated this landmark by using it for treatment in 13 patients. Further studies evaluating clinical outcomes following sacroplasty will be necessary.
Collapse
|